Updated:
TScan Therapeutics
TScan was founded in 2018 by Dr. Stephen Elledge, a Harvard Medical School geneticist, to commercialize a platform that screens genome-wide libraries to...
TScan Therapeutics
TScan was founded in 2018 by Dr. Stephen Elledge, a Harvard Medical School geneticist, to commercialize a platform that screens genome-wide libraries to identify antigens T cells recognize. Former Inotek Pharmaceuticals CEO David Southwell has served as chief executive since 2020, steering the company through a $100 million Series C in 2020 and its July 2021 initial public offering on Nasdaq. The company deploys its proprietary target-discovery engine to develop TCR-engineered T-cell therapies. One clinical arm addresses hematologic cancers via a multiplexed approach that targets multiple tumor-associated antigens simultaneously to prevent relapse. The second arm focuses on solid tumors using a custom screening method to match patients with their unique cancer antigens. The pipeline includes TSC-100 and TSC-101 for blood cancers and a deeper solid-tumor portfolio featuring TSC-204, among others. Named collaborators and investors have included Novartis Institutes for BioMedical Research and GV, reflecting early external validation of the platform science. The firm operates from headquarters in Waltham, Massachusetts, employing approximately 270 professionals across research, clinical, and manufacturing functions. This team supports internal process development and clinical supply for its cell therapy candidates, a function many peers outsource. In December 2023, Amgen committed to a collaboration — paying an undisclosed upfront sum to leverage TScan's target-discovery platform for new cancer target identification, adding a non-dilutive capital stream alongside its public-market access. TScan's structural distinction is its vertically integrated cell-therapy manufacturing capability. The Waltham facility handles process development and clinical production in-house, which shortens the feedback loop between research and the clinic. That integration, coupled with a platform that discovers novel targets rather than engineering existing ones, creates a moat around target identification that is chemically distinct from competitors relying on known cancer-testis antigens.
General information
Firm type
Asset Manager
Year founded
2018
AUM
Undisclosed
Location
Region
North America
Country
United States
City
Waltham
Corporate office
Waltham, MA, United States
Principals
David P. Southwell
President and Chief Executive Officer
Debora Barton
Chief Medical Officer
Gavin MacBeath
Chief Scientific Officer
Sector focus
Frequently asked questions
What is TScan's core technology platform?
TScan uses a genome-wide, high-throughput method invented by founder Stephen Elledge to screen T cells against every protein in the human genome and identify the specific antigens they recognize. That antigen map then informs the design of TCR-engineered T-cell therapies, allowing the company to discover novel tumor targets rather than rely solely on previously characterized cancer antigens.
How does TScan's therapeutic approach differ from CAR-T companies?
TScan develops TCR-engineered T-cell therapies, which recognize intracellular protein fragments presented on the cell surface by HLA molecules, while CAR-T therapies typically target only surface proteins. This gives TCR therapy access to a far larger pool of cancer targets. TScan's platform also scans for multiple antigens simultaneously to combat tumor heterogeneity and immune escape in hematologic cancers.
Who are TScan's key strategic partners?
Amgen entered a multi-year collaboration with TScan in December 2023 to use its screening platform for identifying new cancer targets. The company also has an existing relationship with Novartis Institutes for BioMedical Research to discover targets for TCR-based therapies across multiple indications.
What is TScan's pipeline focus?
The pipeline splits into two arms. A multiplexed hematologic cancer program aims to prevent relapse by targeting multiple tumor-associated antigens in a single engineered product. Its solid-tumor program uses a patient-specific screening approach to identify and attack unique cancer antigens, with lead candidates including TSC-204.
Where does TScan manufacture its cell therapies?
TScan operates its own process development and clinical manufacturing facility at its Waltham, Massachusetts headquarters. Internal manufacturing lets the company control the cell-therapy supply chain and iterate more rapidly between research observations and clinical-grade material production.
Profile maintained by Altss using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.
Need institutional-grade insight on family offices?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: